AbbVie Inc. reported fourth‑quarter 2025 results on February 4, 2026, delivering total revenue of $16.62 billion, a 10 % year‑over‑year increase from $15.102 billion in Q4 2024. Adjusted diluted earnings per share rose to $2.71, beating the consensus estimate of $2.66 by $0.05 per share.
Revenue growth was driven by robust demand in the immunology and neuroscience portfolios. Skyrizi and Rinvoq each grew roughly 30 % YoY, while Humira sales fell 26 % to $X (not specified) but still exceeded forecasts by over $200 million, underscoring the resilience of AbbVie’s legacy product amid biosimilar competition.
Operating margin expanded to 27.3 % in Q4 2025, up from 34.7 % in the prior year, reflecting a favorable product mix and disciplined cost management. The company generated strong operating cash flow, with full‑year 2024 cash flow reported at $18.81 billion, and continued to invest heavily in its pipeline.
AbbVie guided 2026 adjusted diluted EPS to $14.37–$14.57, a range that exceeds analyst expectations and signals confidence in sustained growth. The guidance follows a 9 % year‑over‑year increase in full‑year 2025 revenue to $61.6 billion and a slight 1.2 % decline in full‑year EPS to $10.00.
CEO Robert A. Michael said the company’s momentum remains strong, noting that 2025 was the second full year after Humira’s U.S. exclusivity loss and that the diversified growth platform continues to deliver record net sales. He highlighted strategic investments in high‑return areas and the expansion of the pipeline.
Investors reacted negatively to the earnings release, citing concerns over Humira’s declining sales and broader economic uncertainty. Despite the earnings beat and forward guidance, the market’s focus on the biosimilar headwinds and the company’s ongoing transition away from Humira tempered enthusiasm.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.